Internal Medicine CME Courses

This is an online, self online CME self-learning program for therapeutic updates, best practices, and emerging therapies for Chronic inflammatory demyelinating polyneuropathy (CIDP). Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic, acquired, autoimmune disorder affecting the peripheral nervous system. Occurring at an incidence of 4-9 people per 100,000, CIDP most commonly occurs in adults aged of 40 to 60, although it may also occur in children and the elderly.

By the end of the session the participant will be able to:

• Describe the pathophysiology of CIDP such that it might inform treatment mechanisms
• Identify the currently available and emerging pharmacotherapeutic treatments for management of CIDP and apply them to patient cases using evidence-based medicine
• Modify an existing treatment plan for a specific patient with CIDP to optimize safety and efficacy following non-response to therapy
• Describe non-pharmacological options to manage CIDP
  
  

At the conclusion of this activity, participants will be able to:

1. Discuss the problem of “financial harm” for individual patients
2. List the three steps of the “First, Do No Financial Harm” framework
3. Demonstrate strategies for discussing costs and the value of recommended medical procedures with price-sensitive patients

By the end of the session the participant will be able to:

• Describe the role of the immune system in cancer and cancer therapy in metastatic melanoma.
• Distinguish between the different forms of therapy presently approved for metastatic melanoma and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
• Describe emerging (investigational) therapies for metastatic melanoma
• Describe the challenges and barriers to care associated with treating patients with metastatic melanoma

Speakers

• George T. Grossberg, MD Samuel W. Fordyce Professor; Director, Geriatric Psychiatry Department of Psychiatry and Behavioral Neuroscience, Saint Louis University School of Medicine
• David Beck, MD Associate Professor, Department of Psychiatry and Behavioral Neuroscience, Saint Louis University School of Medicine

Topic and Learning Objectives

• Identify different and various forms of agitation among patients with Alzheimer's disease (AD).
• Review proposed mechanisms underlying agitation in AD and how pharmacologic agents may affect them
• Evaluate body of evidence of current and emerging pharmacologic agents for the management of agitation/aggression in patients with AD

By the end of the session the participant will be able to:

• Describe the role of the immune system in cancer and cancer therapy in metastatic melanoma.
• Distinguish between the different forms of therapy presently approved for metastatic melanoma and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
• Describe emerging (investigational) therapies for metastatic melanoma
• Describe the challenges and barriers to care associated with treating patients with metastatic melanoma

A four-part lecture series covering topics in insulin replacement for patients with type 2 diabetes mellitus (T2DM).